Post The Parker Institute touts early results in pancreatic cancer trial — and a new model to accelerate drug development
Post The Emergence of Philanthropy to Fund High-Risk, High-Reward Cancer Research A Conversation With Jeffrey Bluestone, PhD
Post Friends and Parker Institute for Cancer Immunotherapy Co-Host Summit: Optimizing the Use of Immunotherapy
Post Parker Institute for Cancer Immunotherapy Announces Appointment of Bob Purcell as Chief Communications Officer
Post Parker Institute for Cancer Immunotherapy Announces Appointment of Mark Veich as Chief Organizational Advancement Officer